ImmuPharma's H1 financials boosted by Lupuzor progress
This article was originally published in Scrip
ImmuPharma has reported revenues of £21.6 million and net profit of £11.7 million in the first half of 2009, up from £97,000 and a net loss of £1.5 million respectively in the same period last year. The company's cash and cash equivalents rose from £12.5 million at the end of December 2008 to £27.1 million on June 30th, 2009.
You may also be interested in...
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.